Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as VHX-896
VHX-896 and iloperidone · 1 trial · 2 indications
As measured by plasma concentrations
| Arm | Type | Description |
|---|---|---|
| Sequence A: VHX-896 then iloperidone | EXPERIMENTAL | - |
| Sequence B: Iloperidone then VHX-896 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| VHX-896 and iloperidone | DRUG | oral tablet |
| Iloperidone and VHX-896 | DRUG | oral tablet |
Inclusion Criteria: * Male or female patients 18 to 65 years of age (inclusive) * Diagnosed with either schizophrenia or bipolar I disorder, manic or mixed type, according to the Diagnostic and Statistical Manual of Mental Disorder, Fifth Edition, Text Revision (DSM-5-TR) * Patients must be symptom...
Top 15 of 16 competitors
VHX-896 is an investigational small molecule being developed by Vanda Pharmaceuticals Inc. (ticker: VNDA) for schizophrenia. It is in Phase 1 clinical development. VHX-896 is also known as iloperidone. It has been studied in a single completed Phase 1 pharmacokinetic trial.
VHX-896 is being developed for the treatment of schizophrenia. The completed Phase 1 trial of VHX-896 also enrolled patients with Bipolar I Disorder. VHX-896 is investigational and has not been approved for any indication.
VHX-896 is being developed by Vanda Pharmaceuticals Inc., which trades on the Nasdaq under the ticker symbol VNDA. Vanda is the sponsor of the clinical program for VHX-896.
VHX-896 is in Phase 1 clinical development. One Phase 1 trial of VHX-896 has been completed, and no active trials are currently listed. VHX-896 is investigational and has not received FDA approval.
VHX-896 has been studied in one completed Phase 1 trial, NCT06494397, titled a Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions. The trial enrolled 26 participants in the United States, was randomized and controlled, and included adults 18 years and older.
Yes, VHX-896 is also known as iloperidone. Vanda Pharmaceuticals Inc. is developing VHX-896, and the completed Phase 1 trial NCT06494397 studied VHX-896 and iloperidone tablets under steady-state conditions in 26 participants with schizophrenia or Bipolar I Disorder.